Antibody Engineering & Therapeutics

New Technologies, R&D Advances and Clinical Data to Help you Fast-Track Next Generation Therapeutics to Market

• NEW! Workshop on Engineering Strategies for TCR and CAR T Cell Therapies
• NEW! World-Renowned Academic and Industry Keynotes
• NEW! Location in Kyoto, Japan
• EXPANDED! More Confirmed Speakers from Leading US and European Antibody Companies
• EXPANDED! More Science and Data - 80% of Speakers Are New This Year
• EXPANDED! Exhibit and Poster Sessions

The Latest Scientific Case Studies and Data from Global Companies at the Forefront of Discovery

• Invenra, Amgen, Argenx, Xencor, Immatics and AbbVie will present breakthrough case studies and cutting-edge data
• Eisai will unveil the latest development of Novel Anti-Tau Antibody
• NBE-Therapeutics will provide an update on  NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate
• Sai Reddy will uncover his data on how deep learning enables therapeutic antibody optimization in mammalian cells
• Genentech will detail MerTK Blockade which enhances anti-tumor immunity
• Dainippon Sumitomo's Antibody Intracellular Activated Drug Conjugate (AiADC) as a novel ADC technology

Novel Approaches to Accelerate Therapeutic Development To Be Covered

• Sally Ward’s Research on Targeting Intracellular Trafficking Pathways for the Design of Therapeutics
• Shohei Koide’s Advances in Novel Therapeutics Based on Synthetic Binding Proteins
• Lava Therapeutics’ Novel Bispecific γδ-T cell Engagers for the Treatment of Cancer
• Chugai’s Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
• Takeda’s Vision for Antibody Drug Discovery: An Overview of Programs and Progress
• Koji Tamada’s Prime CAR Technology, a Novel Platform of T cell Therapy Against Solid Tumors